Tiberius (TIBR) Files for a “Fail-safe” Extension
by Kristi Marvin on 2020-02-27 at 5:28pm

Tiberius Acquisition Corp. (TIBR), announced today that in addition to their shareholder vote to complete their business combination with International General Insurance Holdings Limited (“IGI”), on March 13th, 2020, they will also be holding an extension vote on March 19th.

However, this is not unusual. Trinity Merger Corp., which is now Broadmark Realty (BRMK), had to do something similar since their vote date was very close to their expiration date as well.  A SPAC in that situation runs the risk of having a deal voted through, but running over their allotted time due to closing mechanics.  So think of this extension vote as Tiberius’s “fail-safe” insurance policy…which is fitting since they are buying IGI.

However, the particulars are that the extension vote will take place a few days after the combination vote, so this is only going to happen if they can’t get the paperwork done, or there’s a snowstorm or God forbid, there isn’t enough staff around due to the Coronavirus to actually mechanically close the deal.  It would be a real kick in the pants to have come this far and have a deal NOT close due to a technicality such as needing one more day for paperwork.

As such, there is no contribution to trust for Tiberius’s extension (it’s not that kind of an extension) and they are only asking for one month by extending to April 20th, 2020. Furthermore, this extension might not even happen if they can close the combination ahead of the extension vote.

However, as with any shareholder vote, shareholders will have the ability to redeem their shares at Tiberius’s extension vote. However, only shareholders who did not elect to redeem previously at the combination vote will be eligible to redeem at the extension vote.  And as is typical for SPACs, the redemption deadline to redeem at the extension vote will be two days prior, or March 17th.  Keep in mind that the combination vote date is March 13th, which means we will most likely not get any vote/redemption results right away since any information could potentially sway the extension results.  (Record date is February 14th, 2020)

All told, Tiberius has secured all the necessary regulatory approvals now from the UK Prudential Regulation Authority (PRA), Financial Conduct Authority (FCA), Bermuda Monetary Authority (BMA) and Dubai Financial Services Authority (DFSA), so it’s full steam ahead.  We should have a result in roughly three weeks time.

 

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved